Curis CEO Ali Ph.D. Fattaey Purchases 62,890 Shares (CRIS)
Curis (NASDAQ:CRIS) CEO Ali Ph.D. Fattaey acquired 62,890 shares of the stock in a transaction that occurred on Wednesday, August 27th. The stock was purchased at an average price of $1.60 per share, for a total transaction of $100,624.00. Following the completion of the acquisition, the chief executive officer now directly owns 65,890 shares in the company, valued at approximately $105,424. The purchase was disclosed in a document filed with the SEC, which is available at this link.
Separately, analysts at Zacks downgraded shares of Curis from an “outperform” rating to a “neutral” rating in a research note on Tuesday, August 12th. They now have a $2.10 price target on the stock. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Curis currently has a consensus rating of “Buy” and an average target price of $4.66.
Curis (NASDAQ:CRIS) traded up 6.92% on Thursday, hitting $1.70. The stock had a trading volume of 1,163,987 shares. Curis has a one year low of $1.53 and a one year high of $4.74. The stock’s 50-day moving average is $1.73 and its 200-day moving average is $2.20. The company’s market cap is $146.2 million.
Curis (NASDAQ:CRIS) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.03. The company had revenue of $4.80 million for the quarter, compared to the consensus estimate of $3.46 million. During the same quarter in the previous year, the company posted ($0.02) earnings per share. The company’s revenue for the quarter was down 11.1% on a year-over-year basis. Analysts expect that Curis will post $-0.18 EPS for the current fiscal year.
Curis, Inc is a drug discovery and development company that is committed to leveraging signaling pathway drug technologies in seeking to develop next generation network-targeted cancer therapies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.